SUNDANCE Trial: Phase II Trial of Sunitinib as Maintenance Therapy After Stereotactic Radiosurgery in Patients With 1-3 Newly Diagnosed Brain Metastases.
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2015
At a glance
- Drugs Sunitinib (Primary)
- Indications Brain metastases; Cancer
- Focus Therapeutic Use
- Acronyms SUNDANCE
- 28 Sep 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 May 2013 Planned end date changed from 1 Aug 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.
- 14 May 2012 Actual patient number is 14 as reported by ClinicalTrials.gov.